MX2019007352A - Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y transtornos musculares. - Google Patents

Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y transtornos musculares.

Info

Publication number
MX2019007352A
MX2019007352A MX2019007352A MX2019007352A MX2019007352A MX 2019007352 A MX2019007352 A MX 2019007352A MX 2019007352 A MX2019007352 A MX 2019007352A MX 2019007352 A MX2019007352 A MX 2019007352A MX 2019007352 A MX2019007352 A MX 2019007352A
Authority
MX
Mexico
Prior art keywords
amino acid
methods
disorders
treatment
acid compositions
Prior art date
Application number
MX2019007352A
Other languages
English (en)
Spanish (es)
Inventor
Afeyan Raffi
Hamill Michael
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of MX2019007352A publication Critical patent/MX2019007352A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2019007352A 2016-12-19 2017-12-19 Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y transtornos musculares. MX2019007352A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662436073P 2016-12-19 2016-12-19
US201762443205P 2017-01-06 2017-01-06
US201762491776P 2017-04-28 2017-04-28
US201762545358P 2017-08-14 2017-08-14
US201762576321P 2017-10-24 2017-10-24
PCT/US2017/067368 WO2018118957A1 (en) 2016-12-19 2017-12-19 Amino acid compositions and methods for the treatment of muscle diseases and disorders

Publications (1)

Publication Number Publication Date
MX2019007352A true MX2019007352A (es) 2019-09-05

Family

ID=61025047

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007352A MX2019007352A (es) 2016-12-19 2017-12-19 Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y transtornos musculares.

Country Status (21)

Country Link
US (3) US20180207119A1 (cg-RX-API-DMAC7.html)
EP (1) EP3554493A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020502183A (cg-RX-API-DMAC7.html)
KR (1) KR20190099243A (cg-RX-API-DMAC7.html)
CN (1) CN110267655A (cg-RX-API-DMAC7.html)
AU (1) AU2017379825A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019012476A2 (cg-RX-API-DMAC7.html)
CA (1) CA3046558A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001685A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019006292A2 (cg-RX-API-DMAC7.html)
CU (1) CU20190057A7 (cg-RX-API-DMAC7.html)
EC (1) ECSP19043725A (cg-RX-API-DMAC7.html)
IL (1) IL267210A (cg-RX-API-DMAC7.html)
JO (1) JOP20190147A1 (cg-RX-API-DMAC7.html)
MA (1) MA50763A (cg-RX-API-DMAC7.html)
MX (1) MX2019007352A (cg-RX-API-DMAC7.html)
PE (1) PE20191206A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501339A1 (cg-RX-API-DMAC7.html)
TW (1) TWI780096B (cg-RX-API-DMAC7.html)
WO (1) WO2018118957A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201903581B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2018201024A1 (en) 2017-04-28 2018-11-01 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
BR112020002419A2 (pt) 2017-08-14 2020-07-28 Axcella Health Inc. aminoácido para o tratamento de doença do fígado
AU2018318091A1 (en) * 2017-08-14 2020-02-13 Axcella Health Inc. Amino acid compositions for the treatment of neuronal injury
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
EP3810168A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Methods of manufacturing amino acid compositions
JP2021529736A (ja) * 2018-06-20 2021-11-04 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 炎症の軽減又は治療のための組成物及び方法
EP3856167A1 (en) * 2018-09-27 2021-08-04 Société des Produits Nestlé S.A. Use of histidine, glycine and other aminoacids for preventing insulin resistance and/or diabetes
US12317914B2 (en) 2019-06-07 2025-06-03 Societe Des Produits Nestle S.A. Compositions and methods using one or more autophagy-inducing amino acids to potentiate musculoskeletal effect of one or more anabolic amino acids
US20220184015A1 (en) * 2019-06-20 2022-06-16 Societe Des Produits Nestle S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids on bone health
KR102456270B1 (ko) * 2019-09-24 2022-10-19 마이오텍사이언스 주식회사 비천연 아미노산 유도체를 함유하는 근감소증의 예방 또는 치료용 약학적 조성물
KR102338447B1 (ko) * 2019-09-24 2021-12-14 마이오텍사이언스 주식회사 비천연 아미노산을 함유하는 근감소증의 예방 또는 치료용 약학적 조성물
US20220331290A1 (en) * 2019-09-24 2022-10-20 Myo-Tec-Sci Pharmaceutical composition for preventing or treating sarcopenia, containing unnatural amino acid
CN110801007A (zh) * 2019-12-17 2020-02-18 苟春虎 老年肌少症营养肽
US20230089723A1 (en) * 2020-03-06 2023-03-23 Axcella Health Inc. Amino acid compositions and methods for muscle and myotube modulation
KR102802853B1 (ko) * 2021-02-26 2025-05-07 이엑스헬스케어 주식회사 피부 유래 엑소좀을 통해 근손실 억제 또는 근생성 촉진 효과를 나타내는 조성물
CN113288890B (zh) * 2021-06-21 2022-02-22 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
WO2024026307A1 (en) 2022-07-25 2024-02-01 Axcella Health Inc. Biomarker for long covid and fatigue
WO2024030909A1 (en) 2022-08-01 2024-02-08 Axcella Health Inc. Biomarkers of amino acid composition treatment response in long covid
WO2025167857A1 (zh) * 2024-02-06 2025-08-14 南京纽邦生物科技有限公司 用于增强或改善肌肉功能和/或提高运动表现和/或预防或缓解疲劳的方法和组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006907A1 (en) * 2000-02-01 2002-01-17 Paul Gardiner Alpha lipoic acid based food supplement for increasing lean muscle mass and strength
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
WO2006009975A2 (en) * 2004-06-22 2006-01-26 Maxim Pharmaceuticals, Inc. Histamine to treat disorders affecting muscle function
EP1865944B1 (en) * 2005-03-29 2018-08-29 Ajinomoto Co., Inc. Amino acid-containing composition used for preventing or remedying decrease in skeletal muscle mass of aged people, comprising L-leucine
JP2007023921A (ja) * 2005-07-19 2007-02-01 Toyota Motor Corp 内燃機関の制御装置
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
CN100518815C (zh) * 2007-02-15 2009-07-29 北京苏里曼医药科技有限公司 一种氨基酸组合物
EP2744356A4 (en) * 2011-08-19 2015-05-27 Musclepharm Corp COMPOSITIONS AND METHODS FOR INHIBITING INCOUNTERANCE IN ANIMALS
EP3060231A1 (en) * 2013-10-23 2016-08-31 The Whitehead Institute for Biomedical Research Mtorc1 modulation by amino acids and uses thereof

Also Published As

Publication number Publication date
ZA201903581B (en) 2020-12-23
PE20191206A1 (es) 2019-09-10
IL267210A (en) 2019-08-29
CL2019001685A1 (es) 2019-08-30
US20180207119A1 (en) 2018-07-26
US20180169046A1 (en) 2018-06-21
US20180169047A1 (en) 2018-06-21
KR20190099243A (ko) 2019-08-26
EP3554493A1 (en) 2019-10-23
PH12019501339A1 (en) 2019-09-30
JP2020502183A (ja) 2020-01-23
JOP20190147A1 (ar) 2019-06-18
CO2019006292A2 (es) 2019-06-28
WO2018118957A1 (en) 2018-06-28
ECSP19043725A (es) 2019-07-31
CA3046558A1 (en) 2018-06-28
BR112019012476A2 (pt) 2020-04-14
TWI780096B (zh) 2022-10-11
MA50763A (fr) 2019-10-23
CN110267655A (zh) 2019-09-20
TW201827068A (zh) 2018-08-01
CU20190057A7 (es) 2020-02-04
AU2017379825A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
PH12019501339A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
ZA202001057B (en) Inhibiting ubiquitin specific peptidase 30
PH12019500204A1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
CO2020001702A2 (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
EA201691567A1 (ru) Способы лечения легких травм головного мозга
PH12018501443A1 (en) Methods of administering hepcidin
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
PH12019501358A1 (en) Methods of administering hepcidin
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
EA201991504A1 (ru) Композиции на основе аминокислот и способы лечения заболеваний и нарушений мышц
EA201592012A1 (ru) Применение флагеллина для улучшенной химиотерапии
HK40013671A (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
IN2013MU03429A (cg-RX-API-DMAC7.html)